Charles Weston

Joseph Hedden

Brendan Smith

Christian Ehmann

Douglas Tsao

Fynn Scherzler

Michael Ryskin

Benjamin Jackson

David Floren

Falko Friedrichs

James Quigley

Peter Verdult

Steven Mah

Thibault Boutherin

Wolf Chanoff

- Dewpoint Therapeutics, in partnership with **Evotec**, has announced the opening of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for **DPTX3186**, a first-in-class oral condensate modulator.  **[1412558_c8864863c4cd42b88bc84e2d615447be_1]** 
- **Evotec** provided **integrated support** across preclinical, regulatory, and CMC, leveraging its expertise to advance DPTX3186 from a de novo candidate to a clinically ready investigational therapy.  **[1412558_c8864863c4cd42b88bc84e2d615447be_1]** 
- First patient dosing for DPTX3186 is planned before **year-end 2025** in a combined Phase 1/2 trial for gastric and other Wnt-driven cancers.  **[1412558_c8864863c4cd42b88bc84e2d615447be_0]** **[1412558_c8864863c4cd42b88bc84e2d615447be_1]**

Evotec Partner Dewpoint Therapeutics Announces IND Opening for DPTX3186

Evotec (EVO)